Highlight
This national Spanish study establishes the prevalence of donor cell-derived hematologic neoplasms (DDHN) at 0.28% among allogeneic hematopoietic stem cell transplants (allo-HSCT), highlighting a significantly higher risk associated with related-donor transplants. Germline mutations, particularly in DDX41, emerge as the primary molecular underpinning, emphasizing the importance of pre-transplant germline genetic screening.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
